FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis

BACKGROUND: The efficacy of oxaliplatin-based chemotherapy combined with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) remains controversial in metastatic colorectal cancer (mCRC). This meta-analysis aims to estimate the effect of adding panitumumab or cetuximab to oxaliplat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Datian, Li, Li, Zhang, Xiang, Gao, Guangyi, Shen, Lili, Hu, Jing, Yang, Mi, Liu, Baorui, Qian, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882422/
https://www.ncbi.nlm.nih.gov/pubmed/29517682
http://dx.doi.org/10.1097/MD.0000000000010097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882422/
https://www.ncbi.nlm.nih.gov/pubmed/29517682
http://dx.doi.org/10.1097/MD.0000000000010097

Ejemplares similares